GlassScriptPhysician profile
Dan R Spearman
NPI 1962475905
$3,500.82
in general payments reported to CMS, 2019-2025
28 companies · $53.88 in 2025
The $53.88 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $873 · 2020: $229 · 2021: $792 · 2022: $698 · 2023: $362 · 2024: $493 · 2025: $53.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $501.86 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, LP | $473.35 | 2019-2024 | Cotempla Xr-Odt |
| Supernus Pharmaceuticals, INC. | $438.37 | 2021-2024 | Qelbree, Qelbree |
| Corium, LLC | $350.71 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $320.07 | 2019-2022 | |
| Glaxosmithkline, LLC. | $238.14 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Merck Sharp & Dohme LLC | $211.20 | 2019-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Kaleo, INC. | $204.87 | 2019-2022 | |
| Pfizer INC. | $152.93 | 2019-2023 | |
| Tris Pharma INC | $148.40 | 2019-2023 | Dyanavel Xr |
| Cranial Technologies, INC | $97.12 | 2022-2024 | Doc Band |
| Sanofi Pasteur INC. | $51.29 | 2021 | |
| Vertical Pharmaceuticals, LLC | $41.27 | 2019-2025 | Relexxii |
| Sobi, INC | $31.54 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $28.97 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rhodes Pharmaceuticals L.P. | $27.61 | 2019 | |
| Seqirus USA INC | $19.94 | 2023 | Flucelvax Quadrivalent |
| Alk-Abello, INC | $18.80 | 2024 | Grastek, Ragwitek, Odactra |
| Phadia US INC. | $18.70 | 2019 | |
| Neurelis, INC. | $18.50 | 2021 | |
| Hologic Sales and Service, LLC | $18.16 | 2023 | Aptima |
| Verrica Pharmaceuticals INC. | $15.05 | 2023 | Ycanth |
| Adlon Therapeutics L.P. | $13.44 | 2019 | |
| Aytu Biopharma, INC. | $12.86 | 2021 | |
| Shire North American Group INC | $12.63 | 2019 | |
| Masimo Corporation | $12.52 | 2019 | |
| Concordia Pharmaceuticals INC. | $11.69 | 2019 | |
| Mylan Pharmaceuticals INC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Spearman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.